What is Amicus Therapeutics?
Amicus Therapeutics operates as a global, patient-dedicated biotechnology enterprise. The firm is primarily engaged in the discovery, development, and delivery of novel, high-quality therapeutic interventions for individuals suffering from rare metabolic diseases. By maintaining a specialized focus on complex biological pathways, Amicus has established a robust pipeline that bridges the gap between laboratory innovation and commercial-scale patient care. Its market position is defined by a commitment to precision medicine, ensuring that therapeutic solutions are tailored to the specific physiological requirements of patient populations that have historically been underserved by traditional pharmaceutical models.
How much funding has Amicus Therapeutics raised?
Amicus Therapeutics has raised a total of $475M across 2 funding rounds:
Stock Offering
$75M
Debt
$400M
Stock Issuance/Offering (2007): $75M, investors not publicly disclosed
Debt (2020): $400M led by Hayfin Capital Management LLP
Key Investors in Amicus Therapeutics
Hayfin Capital Management LLP
A leading alternative asset management firm that provides bespoke financing solutions and debt capital to high-growth companies across various sectors.
Undisclosed Investor
An institutional participant providing essential equity backing during the company's foundational growth phase.
What's next for Amicus Therapeutics?
With the recent influx of capital, Amicus Therapeutics is well-positioned to accelerate its late-stage clinical programs and expand its global commercial footprint. The strategic deployment of these funds will likely prioritize the scaling of manufacturing capabilities and the enhancement of distribution networks for its flagship therapies. As the company transitions into a more mature phase of its lifecycle, the focus will shift toward sustaining long-term growth through the diversification of its therapeutic portfolio and the pursuit of regulatory approvals in emerging international markets. This financial stability provides the necessary runway to navigate the complexities of the biotech regulatory environment while maintaining a competitive edge in the development of next-generation metabolic treatments.
See full Amicus Therapeutics company page
